Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study

Document Type : Review Paper

Authors

1 Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran

2 Department of Pharmacology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

3 Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.

4 Neuroscience Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Reproductive Sciences and Technology Research Center, Department of Anatomy, Iran University of Medical Sciences, Tehran, Iran.

10.22037/ijpr.2021.114918.15106

Abstract

As a strong and addictive psychostimulant, methamphetamine (METH) is often misused worldwide. Although relapse is the greatest challenge to the effective treatment of drug dependency, now, for METH addiction, there is not available accepted pharmacotherapy. To characterize a probable new target in this indication, a biological system comprised of endocannabinoids, known as the endocannabinoid system (ECS), has been advised. As a non-psychotomimetic Phytocannabinoid in Cannabis sativa, cannabidiol (CBD) has been used in preclinical and clinical studies for treating neuropsychiatric disorders. In this review article, we focus on the effects of CBD in the treatment of addiction in a preclinical investigation concerning the pharmaceutic effectiveness and the underlying mechanisms of action on drug abuse specially METH. Growing evidence shows that CBD is a potential therapeutic agent in reducing drug reward, as evaluated in conditioned place preference (CPP), brain-stimulation reward paradigms, and self- administration. Furthermore, CBD plays an effective role in decreasing relapse in animal research. Through multiple-mechanisms, there is a belief that CBD modulates brain dopamine responding to METH, resulting in a reduction of METH-seeking behaviors. As our studies indicate, CBD can decrease METH addiction-associated problems, for example, symptoms of withdrawal and craving. It is needed for conducting more preclinical investigations and upcoming clinical trials to entirely assess the CBD capability as interference for METH addiction.

Graphical Abstract

Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study

Keywords


References
(1) van Amsterdam J, Pennings E, Brunt T and van den
Brink W. Physical harm due to chronic substance
use. Regul. Toxicol. Pharmacol. (2013) 66: 83-7.
(2) Hall W and Degenhardt L. The adverse health
effects of chronic cannabis use. Drug Test. Anal.
(2014) 6: 39-45.
(3) Haile CN, Mahoney III JJ, Newton TF and De
La Garza II R. Pharmacotherapeutics directed at
deficiencies associated with cocaine dependence:
focus on dopamine, norepinephrine and glutamate.
Pharmacol. Ther. (2012) 134: 260-77.
(4) Baicy K and London ED. Corticolimbic
dysregulation and chronic methamphetamine
abuse. Addiction. (2007) 102: 5-15.
(5) Meredith CW, Jaffe C, Ang-Lee K and Saxon AJ.
Implications of chronic methamphetamine use: a
literature review. Harv. Rev. Psychiatry. (2005) 13:
141-54.
(6) Barr AM, Panenka WJ, MacEwan GW, Thornton
AE, Lang DJ, Honer WG and Lecomte T. The
need for speed: an update on methamphetamine
addiction. J. Psychiatry Neurosci. (2006).
(7) Zuardi AW. Cannabidiol: from an inactive
cannabinoid to a drug with wide spectrum of
action. Braz. J. Psychiatry. (2008) 30: 271-80.
(8) Mechoulam R and Carlini EA. Toward drugs
derived from cannabis. Naturwissenschaften.
(1978) 65: 174-9.
(9) Katsidoni V, Anagnostou I and Panagis G.
Cannabidiol inhibits the reward‐facilitating effect
of morphine: involvement of 5‐HT1A receptors in
the dorsal raphe nucleus. Addict. Biol. (2013) 18:
286-96.
(10) Niesink RJ and van Laar MW. Does Cannabidiol
Protect Against Adverse Psychological Effects of
THC? Front. Psychiatry. (2013) 4: 130.
(11) Carbuto M, Sewell RA, Williams A, ForseliusBielen K, Braley G, Elander J, Pittman B,
Schnakenberg A, Bhakta S, Perry E, Ranganathan
M, D’Souza DC and The Yale THC study
group. The safety of studies with intravenous
Δ 9-tetrahydrocannabinol in humans, with case 
161
Razavi Y et al. / IJPR (2021), 20 (4): 152-164
histories. Psychopharmacology. (2012) 219: 885-
96.
(12) Maldonado R, Berrendero F, Ozaita A and Robledo
P. Neurochemical basis of cannabis addiction.
Neuroscience. (2011) 181: 1-17.
(13) Morgan CJ, Freeman TP, Schafer GL and Curran
HV. Cannabidiol attenuates the appetitive effects
of Δ 9-tetrahydrocannabinol in humans smoking
their chosen cannabis. Neuropsychopharmacology.
(2010) 35: 1879-85.
(14) Hay GL, Baracz SJ, Everett NA, Roberts J, Costa
PA, Arnold JC, McGregor IS and Cornish JL.
Cannabidiol treatment reduces the motivation
to self-administer methamphetamine and
methamphetamine-primed relapse in rats. J.
Psychopharmacol. (2018) 32: 1369-78.
(15) Trigo JM, Soliman A, Staios G, Quilty L, Fischer
B, George TP, Rehm J, Selby P, Barnes AJ,
Huestis MA and Foll BL. Sativex associated with
behavioral-relapse prevention strategy as treatment
for cannabis dependence: a case series. J. Addict.
Med. (2016) 10: 274.
(16) Prud’homme M, Cata R and Jutras-Aswad D.
Cannabidiol as an intervention for addictive
behaviors: a systematic review of the evidence.
Subst. Abuse: Res. Treat. (2015) 9:33-8
(17) Razavi Y, Shabani R, Mehdizadeh M and
Haghparast A. Neuroprotective effect of chronic
administration of cannabidiol during the abstinence
period on methamphetamine-induced impairment
of recognition memory in the rats. Behav.
Pharmacol. (2020) 31: 385-96.
(18) Parker LA, Burton P, Sorge RE, Yakiwchuk C
and Mechoulam R. Effect of low doses of delta9-
tetrahydrocannabinol and cannabidiol on the
extinction of cocaine-induced and amphetamineinduced conditioned place preference learning in
rats. Psychopharmacology (Berl) (2004) 175: 360-
6.
(19) Ren Y, Whittard J, Higuera-Matas A, Morris CV
and Hurd YL. Cannabidiol, a nonpsychotropic
component of cannabis, inhibits cue-induced
heroin seeking and normalizes discrete mesolimbic
neuronal disturbances. J. Neurosci. (2009) 29:
14764-9.
(20) Luján MÁ, Castro-Zavala A, Alegre-Zurano L
and Valverde O. Repeated Cannabidiol treatment
reduces cocaine intake and modulates neural
proliferation and CB1R expression in the mouse
hippocampus. Neuropharmacology (2018) 143:
163-75.
(21) Viudez‐Martínez A, García‐Gutiérrez MS,
Navarrón CM, Morales‐Calero MI, Navarrete F,
Torres‐Suárez AI and Manzanares J. Cannabidiol
reduces ethanol consumption, motivation and
relapse in mice. Addict. Biol. (2018) 23: 154-64.
(22) Kashefi A, Tomaz C, Jamali S, Rashidy-Pour
A, Vafaei AA and Haghparast A. Cannabidiol
attenuated the maintenance and reinstatement of
extinguished methylphenidate-induced conditioned
place preference in rats. Brain Res. Bull. (2021)
166: 118-27.
(23) Kathmann M, Flau K, Redmer A, Tränkle C and
Schlicker E. Cannabidiol is an allosteric modulator
at mu-and delta-opioid receptors. Naunyn
Schmiedebergs Arch. Pharmacol. (2006) 372: 354-
61.
(24) Pandolfo P, Silveirinha V, dos Santos-Rodrigues A,
Venance L, Ledent C, Takahashi RN, Cunha RA
and Köfalvi A. Cannabinoids inhibit the synaptic
uptake of adenosine and dopamine in the rat and
mouse striatum. Eur. J. Pharmacol. (2011) 655: 38-
45.
(25) Conrad KL, Ford K, Marinelli M and Wolf ME.
Dopamine receptor expression and distribution
dynamically change in the rat nucleus accumbens
after withdrawal from cocaine self-administration.
Neuroscience. (2010)169: 182-94.
(26) W Stoops W and R Rush C. Agonist replacement
for stimulant dependence: a review of clinical
research. Curr. Pharm. Des. (2013) 19: 7026-35.
(27) Bergamaschi MM, Queiroz RH, Zuardi AW and
Crippa JA. Safety and side effects of cannabidiol,
a Cannabis sativa constituent. Curr. Drug Saf.
(2011) 6: 237-49.
(28) Zhornitsky S and Potvin S. Cannabidiol in humansthe quest for therapeutic targets. Pharm. (Basel)
(2012) 5: 529-52.
(29) Karimi-Haghighi S and Haghparast A. Cannabidiol
inhibits priming-induced reinstatement of
methamphetamine in REM sleep deprived rats.
Prog. Neuropsychopharmacol. Biol. Psychiatry.
(2018) 82: 307-13.
(30) Karimi-Haghighi S, Dargahi L and Haghparast
A. Cannabidiol modulates the expression of
neuroinflammatory factors in stress- and druginduced reinstatement of methamphetamine in
extinguished rats. Addict. Biol. (2020) 25: e12740.
(31) Palazzolo DL and Quadri SK. Interleukin-1
stimulates catecholamine release from the
hypothalamus. Life Sci. (1990) 47: 2105-9.
(32) Shintani F, Kanba S, Nakaki T, Nibuya M,
Kinoshita N, Suzuki E, Yagi G, Kato R and
Asai M. Interleukin-1 beta augments release of
norepinephrine, dopamine, and serotonin in the
rat anterior hypothalamus. J. Neurosci. (1993) 13:
3574-81.
(33) Renard J, Loureiro M, Rosen LG, Zunder J, de 
162
Cannabidiol: A Brief Review of Its Therapeutic Role on Methamphetamine
Oliveira C, Schmid S, Rushlow WJ and Laviolette
SR. Cannabidiol Counteracts AmphetamineInduced Neuronal and Behavioral Sensitization
of the Mesolimbic Dopamine Pathway through a
Novel mTOR/p70S6 Kinase Signaling Pathway. J.
Neurosci. (2016) 36: 5160-9.
(34) Yang G, Liu L, Zhang R, Li J, Leung CK, Huang
J, Li Y, Shen B, Zeng X and Zhang D. Cannabidiol
attenuates methamphetamine-induced conditioned
place preference via the Sigma1R/AKT/GSK-3β/
CREB signaling pathway in rats. Toxicol. Res.
(Camb). (2020) 9: 202-11.
(35) Leweke FM, Piomelli D, Pahlisch F, Muhl D,
Gerth CW, Hoyer C, Klosterkötter J, Hellmich M
and Koethe D. Cannabidiol enhances anandamide
signaling and alleviates psychotic symptoms of
schizophrenia. Transl. Psychiatry. (2012) 2: e94.
(36) Khanegheini A, Khani M, Zarrabian S,
Yousefzadeh-Chabok S, Taleghani BK and
Haghparast A. Cannabidiol enhanced the
development of sensitization to the expression
of methamphetamine-induced conditioned place
preference in male rats. J. Psychiatr. Res. (2021)
137: 260-5.
(37) Hassanlou AA, Jamali S, RayatSanati K, Mousavi
Z and Haghparast A. Cannabidiol modulates the
METH-induced conditioned place preference
through D2-like dopamine receptors in the
hippocampal CA1 region. Brain Res. Bull. (2021)
172: 43-51.
(38) Anooshe M, Nouri K, Karimi-Haghighi S, Mousavi
Z and Haghparast A. Cannabidiol efficiently
suppressed the acquisition and expression of
methamphetamine-induced conditioned place
preference in the rat. Behav. Brain Res. (2021) 404:
113158.
(39) Campos AC, Moreira FA, Gomes FV, Del Bel EA
and Guimarães FS. Multiple mechanisms involved
in the large-spectrum therapeutic potential of
cannabidiol in psychiatric disorders. Philos. Trans.
R. Soc. Lond. B: Biol. Sci. (2012) 367: 3364-78.
(40) Ligresti A, De Petrocellis L and Di Marzo V. From
phytocannabinoids to cannabinoid receptors and
endocannabinoids: pleiotropic physiological and
pathological roles through complex pharmacology.
Physiol. Rev. (2016) 96: 1593-659.
(41) Laprairie RB, Bagher AM, Kelly ME and DenovanWright EM. Cannabidiol is a negative allosteric
modulator of the cannabinoid CB1 receptor. Br. J.
Pharmacol. (2015) 172: 4790-805.
(42) McPartland JM, Duncan M, Di Marzo V
and Pertwee RG. Are cannabidiol and Δ(9)
-tetrahydrocannabivarin negative modulators of
the endocannabinoid system? A systematic review.
Br. J. Pharmacol. (2015) 172: 737-53.
(43) Thomas A, Baillie GL, Phillips AM, Razdan RK,
Ross RA and Pertwee RG. Cannabidiol displays
unexpectedly high potency as an antagonist of
CB1 and CB2 receptor agonists in vitro. Br. J.
Pharmacol. (2007) 150: 613-23.
(44) Laprairie RB, Bagher AM, Kelly ME, Dupré DJ
and Denovan-Wright EM. Type 1 cannabinoid
receptor ligands display functional selectivity
in a cell culture model of striatal medium spiny
projection neurons. J. Biol. Chem. (2014) 289:
24845-62.
(45) Premoli M, Aria F, Bonini SA, Maccarinelli G,
Gianoncelli A, Della Pina S, Tambaro S, Memo
M and Mastinu A. Cannabidiol: Recent advances
and new insights for neuropsychiatric disorders
treatment. Life Sci. (2019) 224: 120-7.
(46) Castillo A, Tolón MR, Fernández-Ruiz J, Romero
J and Martinez-Orgado J. The neuroprotective
effect of cannabidiol in an in-vitro model of
newborn hypoxic-ischemic brain damage in mice
is mediated by CB(2) and adenosine receptors.
Neurobiol. Dis. (2010) 37: 434-40.
(47) Rock EM, Bolognini D, Limebeer CL, Cascio
MG, Anavi-Goffer S, Fletcher PJ, Mechoulam
R, Pertwee RG and Parker LA. Cannabidiol,
a non-psychotropic component of cannabis,
attenuates vomiting and nausea-like behaviour via
indirect agonism of 5-HT(1A) somatodendritic
autoreceptors in the dorsal raphe nucleus. Br. J.
Pharmacol. (2012) 165: 2620-34.
(48) Russo EB, Burnett A, Hall B and Parker KK.
Agonistic properties of cannabidiol at 5-HT1a
receptors. Neurochem. Res. (2005) 30: 1037-43.
(49) Rodríguez-Muñoz M, Sánchez-Blázquez P, Merlos
M and Garzón-Niño J. Endocannabinoid control
of glutamate NMDA receptors: the therapeutic
potential and consequences of dysfunction.
Oncotarget. (2016) 7: 55840-62.
(50) Campos AC and Guimarães FS. Involvement of
5HT1A receptors in the anxiolytic-like effects
of cannabidiol injected into the dorsolateral
periaqueductal gray of rats. Psychopharmacology
(Berl) (2008) 199: 223-30.
(51) Espejo-Porras F, Fernández-Ruiz J, Pertwee RG,
Mechoulam R and García C. Motor effects of the
non-psychotropic phytocannabinoid cannabidiol
that are mediated by 5-HT1A receptors.
Neuropharmacology (2013) 75: 155-63.
(52) Gomes FV, Resstel LB and Guimarães FS. The
anxiolytic-like effects of cannabidiol injected into
the bed nucleus of the stria terminalis are mediated
by 5-HT1A receptors. Psychopharmacology (Berl)
(2011) 213: 465-73.
163
Razavi Y et al. / IJPR (2021), 20 (4): 152-164
(53) Fogaça MV, Reis FM, Campos AC and Guimarães
FS. Effects of intra-prelimbic prefrontal cortex
injection of cannabidiol on anxiety-like behavior:
involvement of 5HT1A receptors and previous
stressful experience. Eur. Neuropsychopharmacol.
(2014) 24: 410-9.
(54) Twardowschy A, Castiblanco-Urbina MA, UribeMariño A, Biagioni AF, Salgado-Rohner CJ, Crippa
JA and Coimbra NC. The role of 5-HT1A receptors
in the anti-aversive effects of cannabidiol on panic
attack-like behaviors evoked in the presence of the
wild snake Epicrates cenchria crassus (Reptilia,
Boidae). J. Psychopharmacol. (2013) 27: 1149-59.
(55) Hayakawa K, Mishima K, Nozako M, Ogata A,
Hazekawa M, Liu AX, Fujioka, Abe K, Hasebe
N, Egashira N, Iwasaki K and Fujiwara M.
Repeated treatment with cannabidiol but not
Delta9-tetrahydrocannabinol has a neuroprotective
effect without the development of tolerance.
Neuropharmacology (2007) 52: 1079-87.
(56) O’Sullivan SE, Sun Y, Bennett AJ, Randall MD
and Kendall DA. Time-dependent vascular actions
of cannabidiol in the rat aorta. Eur. J. Pharmacol.
(2009) 612: 61-8.
(57) Granja AG, Carrillo-Salinas F, Pagani A, GómezCañas M, Negri R, Navarrete C, Mecha M, Mestre
L, Fiebich BL, Cantarero I, Calzado MA, Bellido
ML, Fernandez-Ruiz J, Appendino G, Guaza C
and Muñoz E. A cannabigerol quinone alleviates
neuroinflammation in a chronic model of multiple
sclerosis. J. Neuroimmune. Pharmacol. (2012) 7:
1002-16.
(58) Rajasekaran A, Venkatasubramanian G, Berk
M and Debnath M. Mitochondrial dysfunction
in schizophrenia: pathways, mechanisms and
implications. Neurosci. Biobehav. Rev. (2015) 48:
10-21.
(59) Iannotti FA, Hill CL, Leo A, Alhusaini A,
Soubrane C, Mazzarella E, Russo E, Whalley BJ,
Marzo VD and Stephens GJ. Nonpsychotropic
plant cannabinoids, cannabidivarin (CBDV)
and cannabidiol (CBD), activate and desensitize
transient receptor potential vanilloid 1 (TRPV1)
channels in-vitro: potential for the treatment of
neuronal hyperexcitability. ACS Chem. Neurosci.
(2014) 5: 1131-41.
(60) Campos AC and Guimarães FS. Evidence for
a potential role for TRPV1 receptors in the
dorsolateral periaqueductal gray in the attenuation
of the anxiolytic effects of cannabinoids. Prog.
Neuropsychopharmacol. Biol. Psychiatry (2009)
33: 1517-21.
(61) Costa B, Giagnoni G, Franke C, Trovato AE and
Colleoni M. Vanilloid TRPV1 receptor mediates
the antihyperalgesic effect of the nonpsychoactive
cannabinoid, cannabidiol, in a rat model of acute
inflammation. Br. J. Pharmacol. (2004) 143: 247-
50.
(62) Long LE, Malone DT and Taylor DA. Cannabidiol
reverses MK-801-induced disruption of prepulse
inhibition in mice. Neuropsychopharmacology
(2006) 31: 795-803.
(63) Edwards JG. TRPV1 in the central nervous system:
synaptic plasticity, function, and pharmacological
implications. Prog Drug Res (2014) 77-104.
(64) Bisogno T, Hanuš L, De Petrocellis L, Tchilibon
S, Ponde DE, Brandi I, Moriello AS, Davis JB,
Mechoulam R and Marzo VD. Molecular targets
for cannabidiol and its synthetic analogues: effect
on vanilloid VR1 receptors and on the cellular
uptake and enzymatic hydrolysis of anandamide.
Br. J. Pharmacol. (2001) 134: 845-52.
(65) Galaj E, Bi GH, Yang HJ and Xi ZX. Cannabidiol
attenuates the rewarding effects of cocaine in rats by
CB2, 5-HT1A and TRPV1 receptor mechanisms.
Neuropharmacology (2020) 167: 107740.
(66) Filipović D, Todorović N, Bernardi RE and Gass
P. Oxidative and nitrosative stress pathways
in the brain of socially isolated adult male rats
demonstrating depressive- and anxiety-like
symptoms. Brain Struct. Funct. (2017) 222: 1-20.
(67) Alger BE and Kim J. Supply and demand for
endocannabinoids. Trends Neurosci. (2011) 34:
304-15.
(68) Mecha M, Torrao AS, Mestre L, Carrillo-Salinas
FJ, Mechoulam R and Guaza C. Cannabidiol
protects oligodendrocyte progenitor cells from
inflammation-induced apoptosis by attenuating
endoplasmic reticulum stress. Cell Death Dis.
(2012) 3: e331.
(69) Harvey BS, Ohlsson KS, Mååg JL, Musgrave IF
and Smid SD. Contrasting protective effects of
cannabinoids against oxidative stress and amyloid-β
evoked neurotoxicity in-vitro. Neurotoxicology
(2012) 33: 138-46.
(70) Scuderi C, Steardo L and Esposito G. Cannabidiol
promotes amyloid precursor protein ubiquitination
and reduction of beta amyloid expression in
SHSY5YAPP+ cells through PPARγ involvement.
Phytother. Res. (2014) 28: 1007-13.
(71) Campos AC, Brant F, Miranda AS, Machado FS
and Teixeira AL. Cannabidiol increases survival
and promotes rescue of cognitive function in a
murine model of cerebral malaria. Neuroscience
(2015) 289: 166-80.
(72) Avraham Y, Grigoriadis N, Poutahidis T, Vorobiev
L, Magen I, Ilan Y, Mechoulam R and Berry EM.
Cannabidiol improves brain and liver function in a 
164
Cannabidiol: A Brief Review of Its Therapeutic Role on Methamphetamine
fulminant hepatic failure-induced model of hepatic
encephalopathy in mice. Br. J. Pharmacol. (2011)
162: 1650-8.
(73) Yang L, Rozenfeld R, Wu D, Devi LA, Zhang Z
and Cederbaum A. Cannabidiol protects liver from
binge alcohol-induced steatosis by mechanisms
including inhibition of oxidative stress and increase
in autophagy. Free Radic. Biol. Med. (2014) 68:
260-7.
(74) Koay LC, Rigby RJ and Wright KL. Cannabinoidinduced autophagy regulates suppressor of
cytokine signaling-3 in intestinal epithelium. Am.
J. Physiol. Gastrointest. Liver Physiol. (2014) 307:
G140-8.
(75) Hosseinzadeh M, Nikseresht S, Khodagholi F,
Naderi N and Maghsoudi N. Cannabidiol posttreatment alleviates rat epileptic-related behaviors
and activates hippocampal cell autophagy pathway
along with antioxidant defense in chronic phase
of pilocarpine-induced seizure. J. Mol. Neurosci.
(2016) 58: 432-40.